Retatrutide
Triple GLP-1/GIP/glucagon receptor agonist — next-generation metabolic research compound
Mechanism
What is Retatrutide?
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. It has shown significant weight loss results — up to 24% body weight reduction in Phase 2 trials.
🇦🇺 Australia · TGA
Legal status
Retatrutide is not listed on TGA scheduling. Unscheduled research compound — legal to purchase for research purposes in Australia without a prescription.
This website is intended for research and educational purposes only. The information provided does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any condition. Peptides discussed on this site are not approved by the TGA for human therapeutic use. Always consult a qualified healthcare professional before using any substance.
Full legal guide for Australia →Frequently asked
Common questions
Is retatrutide legal in Australia?
Yes — retatrutide is currently unscheduled under TGA guidelines. It is not approved for therapeutic use but can be purchased for legitimate research purposes without a prescription. Regulatory status may change as it progresses toward approval.
Can I buy retatrutide in Australia?
Retatrutide is available from international research peptide vendors that ship to Australia. It is not available from Australian pharmacies as it has not received TGA therapeutic approval.
How does retatrutide compare to Mounjaro in Australia?
Mounjaro (tirzepatide) is TGA-approved and available via prescription in Australia. Retatrutide is in Phase 3 trials and not yet approved anywhere. As a research compound, it occupies a different regulatory category to approved medicines.
Where to source Retatrutide
Retatrutide in Australia
We verify COA documentation and purity standards before listing any vendor.
Retatrutide in other markets